Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Advertising Citations Remain Rare In 2018

Jan 10 2019

• By Brenda Sandburg

Pink Sheet prespectives 2018 to 2019

Related Content

Rx Ad Studies Target Risk Info Location, Efficacy Framing, Oncology Products

Jul 10 2017

Advertising Enforcement: US FDA Content To Let Competitors 'Duke It Out,' Woodcock Says

Sep 24 2018

PhRMA Criticizes 'Exponential Pace' Of FDA Rx Drug Advertising Studies

Aug 14 2018

Rx Promotion Citations By US FDA Plummet; UCLA Webpage Elicits Final Letter Of 2017

Jan 24 2018

US FDA Calls Foul On CSL Behring Hemophilia Drug Promo

Mar 07 2018

Rx Drug Ads: New US FDA Studies Target Accelerated Approval Information

Mar 12 2018

Trump Administration's Rx Drug Price Disclosure Reg Seen As Unworkable

Oct 21 2018

DDMAC's Latest Exhibit Hall Citation Is Vectibix; Firms Try Multiple Ways To Avoid FDA At Trade Shows

May 26 2010

First Amendment Does Not Block Off-Label Enforcement Actions, FDA Reiterates

Jan 22 2017

Four Ways To Draw DDMAC's Ire: In Print, On A Dosing Card, In A Script, And In Person

Jan 13 2010

Related Companies

ASCEND Therapeutics, LLC

Eisai Co., Ltd.

Jazz Pharmaceuticals plc

Bristol Myers Squibb Company

Eli Lilly and Company

Amgen, Inc.

MannKind Corporation

CSL Limited

Additional Topics

United States Advertising, Marketing & Sales Enforcement Regulation FDA BioPharmaceutical Pink Sheet Perspectives

More from Marketing & Advertising

More from Compliance

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window